Peptide drug conjugates: How the Indena and Chemi partnership is delivering

Peptide drug conjugates (PDCs) are attracting growing attention across the pharmaceutical sector as companies search for more specialised approaches to cancer treatment. Peptide drug conjugates (PDCs) are attracting growing attention across the pharmaceutical sector as companies search for more specialised approaches to cancer treatment. The partnership between Indena and Chemi S.p.A. / Italfarmaco Group reflects the increasing industry interest in peptide-based targeted therapies and the manufacturing expertise required to bring them to market. Specialist CDMOs are unlocking the immense potential of peptide drug conjugates (PDCs). Credit: via Shutterstock. The pharmaceutical industry is investing heavily in therapies capable of delivering high-potent…

Source: Pharmaceutical Technology